Prelude shares jump 12.7% intraday after releasing 2025 financial results and investor materials.

martes, 31 de marzo de 2026, 10:14 am ET1 min de lectura
PRLD--
Prelude Therapeutics surged 12.70% intraday, as the precision oncology company released its 2025 annual financial results and investor presentation materials on March 10, 2026. The company specializes in discovering and advancing novel precision cancer therapies, with multiple clinical and pre-clinical programs and several FDA IND approvals.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios